BetterLife Pharma Inc.

OTCPK:BETR.F Stock Report

Market Cap: US$11.7m

BetterLife Pharma Past Earnings Performance

Past criteria checks 0/6

BetterLife Pharma has been growing earnings at an average annual rate of 31%, while the Pharmaceuticals industry saw earnings growing at 1.8% annually.

Key information

31.0%

Earnings growth rate

58.2%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Oct 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How BetterLife Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:BETR.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Oct 240-441
31 Jul 240-541
30 Apr 240-441
31 Jan 240-331
31 Oct 230-221
31 Jul 230-661
30 Apr 230-661
31 Jan 230-973
31 Oct 220-1283
31 Jul 220-1044
30 Apr 220-1356
31 Jan 220-1255
31 Oct 210-3665
31 Jul 210-4174
30 Apr 210-3972
31 Jan 210-3680
31 Oct 200-2060
31 Jul 200-1550
30 Apr 200-1880
31 Jan 200-2080
31 Oct 190-1180
31 Jul 190-1280
30 Apr 190-950
31 Jan 190-950
31 Oct 180-840
31 Jul 180-430
30 Apr 180-220
31 Jan 180010
31 Oct 170-120
31 Jul 170-320
30 Apr 170-440
31 Jan 170-880
31 Oct 160-16160
31 Jul 160-15150
30 Apr 160-16160
31 Jan 160-15150
31 Oct 150-650
31 Jul 150-650
30 Apr 150-310
31 Jan 150-100
31 Oct 140000
31 Jul 140-100

Quality Earnings: BETR.F is currently unprofitable.

Growing Profit Margin: BETR.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BETR.F is unprofitable, but has reduced losses over the past 5 years at a rate of 31% per year.

Accelerating Growth: Unable to compare BETR.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BETR.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (78.3%).


Return on Equity

High ROE: BETR.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/10 17:53
End of Day Share Price 2025/02/10 00:00
Earnings2024/10/31
Annual Earnings2024/01/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BetterLife Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.